Malaria is a major cause of morbidity worldwide with reports of over 200-500 million infected individuals and nearly 1 million deaths each year. Antibodies have been shown to play a critical role in controlling the blood stage of this disease; however, in malaria-endemic areas antibody immunity is slow to develop despite years of exposure to Plasmodium spp. the causative parasite. Using rodent Plasmodium yoelii YM, we provide evidence that malarial infections result in a decrease in the proportion of DCs that express the B-cell survival factor, BAFF, resulting in a decreased ability of these DCs to support memory B-cell differentiation into antibody secreting cells (ASCs) and/or the survival of ASCs. Further, compared with infected WT mice, ASC numbers were significantly increased in malaria-infected transgenic mice that either overexpressed BAFF or mice with BAFF-independent B-cell survival (B-cell-restricted TRAF3 deletion). Remarkably, BAFF-overexpressing mice were protected from lethal malaria infections, indicating the significance of the role BAFF plays in determining the outcome of malaria infections. These findings describe a previously unappreciated mechanism by which Plasmodium spp. can depress the generation of protective antibody responses.
Introduction
Adults in malaria-endemic areas will at best only develop nonsterile immunity, which protects against clinical symptoms but does not efficiently clear the parasite. Antibodies protect against Correspondence: Dr. Michelle N. Wykes e-mail: Michelle.Wykes@qimr.edu.au malaria [1] but antibody responses in malaria-endemic areas are short-lived [2] . A longitudinal study undertaken in malariaendemic Mali, with intense seasonal transmission of this disease, found that Plasmodium falciparum-specific memory B cells (MBCs) were generated after acute malaria episodes during the wet season [3] . However, similar to short-lived antibody levels [2] , the levels of MBCs diminished considerably within 6 months to slightly higher than preinfection levels despite ongoing malaria episodes [3] . Similarly, a Phase 1 clinical trial of the apical membrane antigen-1 (AMA-1) malaria vaccine, also undertaken in Mali, found that following the second vaccination antibody levels decreased to baseline levels within 1 year, at the time of the third vaccination [4] . The third dose induced little or no increase in antibody levels. This suggests that MBC responses were lost after the second vaccination and thus the third dose was unable to boost antibody levels. In contrast, studies from Madagascar [5] and Thailand [6] with only sporadic malaria transmission found that Plasmodium-specific MBCs survived for several years in individuals who had not been exposed to malaria in the interim. Thus, on-going malarial infections may cause loss of MBC responses not seen with sporadic transmission of malaria.
MSP1 19 , a leading malaria vaccine candidate was tested in clinical trials in Kenya with holoendemic transmission of P. falciparum, and was found to generate very high titers of antibodies but did not protect against infection [7] . An evaluation of this vaccine using an experimental mouse model found that vaccination with MSP1 19 generated MSP1 19 -specific MBCs that when transferred to naïve mice secreted antibody in response to MSP1 19 , but not infection [8] . It was determined that infectious challenge activated MSP1 19 -specific MBCs, which then underwent proliferation followed by apoptosis, thereby resulting in reduced numbers of MSP1 19 -specific antibody-secreting cells (ASCs). Furthermore, this study also showed that the vaccine generated long-lived plasma cells (LLPCs), which secrete high levels of antibody that protect mice against a lethal infection. However, the LLPCs also underwent apoptosis within a few days of infection in this model. Therefore, considering these observations in an experimental model, we propose that with continual exposure to malaria parasites, Plasmodium-specific MBCs may also undergo deletion in malariaendemic areas. Apoptosis of MBCs may explain why antibody responses against the AMA-1 vaccine were not boosted in Mali with ongoing exposure to malaria [4] . The loss of Plasmodiumspecific MBCs following malaria infection would be a potential problem for all antibody-based malarial vaccines. For rational design of a malaria vaccine we need a better understanding of the fate of MBCs in individuals exposed to malaria.
There is growing evidence that DCs play a substantial role in mediating B-cell immunity. DCs can activate naïve B cells and MBCs by presentation of unprocessed antigen directly to B cells [9] [10] [11] , provide proliferation, isotype switch, and survival signals [12] [13] [14] [15] and promote survival in the bone marrow [16] . Furthermore, conventional DCs (cDC) were shown to mediate survival of plasmablasts in spleen and lymph nodes [17] . Most significantly, DCs express BAFF that upregulates antiapoptotic genes in B cells [18] for the survival of ASCs that have differentiated from antigen-activated MBCs [12, 19, 20] . We thus questioned whether altered DC function during malarial infection may contribute to poor survival of vaccine-specific MBCs given that in previous studies, we observed that DCs taken from mice infected with lethal P. yoelii YM malaria were unable to secrete IL-12 and prime T cells [21] . This was also shown in other studies using different rodent parasite species and strains [21] [22] [23] [24] [25] and with human DCs [26] .
In this current study, we used mouse models to measure the contribution of DCs and BAFF to loss of MBC responses against a malaria vaccine (MSP1 19 ) during malaria. The study design was based on the principles that mouse memory B and T cells survive more than 10 weeks after generation, while primary immune responses have subside by this time [27] . Additionally, MBC function is characterized by the production of high titers of IgG antibody within 4-5 days of exposure to antigen, whereas primary B-cell responses require 8-14 days for IgG production. The assays were designed so that similar T-cell help was available to test and control groups, and only differences in MBC responses were measured. Finally, antigen-pulsed DCs were transferred into vaccinated mice to activate MBC responses in vivo as demonstrated for naïve B cells [11] . These approaches were utilized to demonstrate that low BAFF expression on DCs limited MBC responses following malarial infections.
Results
DCs from malaria-infected mice are inefficient at supporting survival of MSP1 19 
-specific ASCs
We previously showed that MSP1 19 -specific MBCs were activated by experimental malaria challenge but following activation, the resultant ASCs underwent apoptosis within 4 days [8] . To determine if a defect in DCs prevented survival of these ASCs, we isolated DCs from naïve, P. yoelii YM (day 7) or P. yoelii 17XNL (day 10) infected mice, pulsed them in vitro with MSP1 19 , and transferred them into MSP1 19 -vaccinated (12-17 weeks after immunization) or naive mice (Fig. 1A) . After 5 days, we enumerated ASCs in the spleen of recipient mice (Fig. 1B) . Previous studies have established that antigen-pulsed DCs take at least 10 days to generate IgG secreting ASCs in naive mice, and that within the 5-day window of the assay used here, only MBCs could generate MSP1 19 -specific IgG ASCs [11] . The various combinations tested are labeled a-e in Fig. 1B .
When DCs were taken from naïve mice, (a) pulsed with MSP1 19 or (b) unpulsed, and transferred to naïve or MSP1 19 -vaccinated mice, respectively, very low numbers of ASCs were generated (Fig. 1B) . In contrast, if DCs were taken from naïve mice, pulsed with MSP1 19 and transferred to MSP1 19 -vaccinated mice, >660% more MSP1 19 -specific ASCs were generated in the recipient mice (c) (Fig. 1B) . Thus the transfer of vaccine-pulsed DCs had an effect similar to a vaccine boost. Significantly, when MSP1 19 -vaccinated mice were given MSP1 19 -pulsed DCs from (d) lethal or (e) nonlethal P. yoelii-infected mice, significantly fewer MSP1 19 -specific ASCs were found, respectively (69 and 34%) compared with those given MSP1 19 -pulsed DCs from naïve mice (Fig. 1B) . These experiments showed that DCs from malaria-infected mice were less efficient at boosting MSP1 19 -specific MBC responses than DCs from naïve mice either by a direct failure to provide MBCs with 19 -specific ASCs/spleen in MSP1 19 -vaccinated mice or naïve mice following transfer of MSP1 19 -pulsed DCs from naïve or infected mice, measured by ELISPOT. The unpulsed DCs from naïve mice show the background levels of ASCs remaining from vaccination. Data are shown as mean ± SEM of 3-5 independently processed mice/group and are representative of three independent assays that gave similar results. Significance was analyzed using the nonparametric Mann-Whitney U test on pooled data from replicate experiments. *p < 0.0115; **p < 0.0374; ***p < 0.0001; NS = Not significant. activation signals or indirect effect such as failure to activate helper T cells.
BAFF expression is reduced on DCs during malaria
As BAFF expression on DCs has been shown to be required for survival of ASCs that had differentiated from antigen-activated MBCs [12, 19, 20] , we next examined BAFF-expression on DCs during P. yoelii infections (Fig. 2) . Groups of mice were infected with P. yoelii YM and DCs were analyzed by flow cytometry at 3 and 7 days postinfection and compared with DCs from naive mice ( Fig. 2A-F) . We examined BAFF expression on two major populations of DCs: B220 + CD11c + plasmacytoid DCs (pDCs) and B220-CD11c+ cDC ( Fig. 2A) . We found that less than 0.5% of pDCs ( Fig. 2C ) and more than 6% of cDCs ( Fig. 2D) (Fig. 2H ). In addition, the level of BAFF expressed on individual cDCs also clearly declined with infection, as shown by the change in mean fluorescence intensity within the BAFF + population (MFI, Fig. 2D -F).
We next examined BAFF expression on DCs from nonlethal P. yoelii 17XNL infections on day 7, to explain their significantly higher support for MSP1 19 -specific ASCs compared with DCs from P. yoelii YM infections (Fig. 1B) . The numbers of cDCs expressing BAFF protein, decreased by nearly 80% within 7 days of infection ( Fig. 2I ), similar to the lethal infection. However, real time PCR studies found that the levels of BAFF mRNA expression on day 7, in CD11c + DCs from nonlethal P. yoelii 17XNL infections was significantly higher than DCs from lethal P. yoelii YM-infected mice (Fig. 2J) . Furthermore, compared with DCs from naïve mice, P. yoelii YM-infected mice had more than 75% reduction in BAFF mRNA in their DCs (Fig. 2J ).
Finally, an examination of overall BAFF expression in spleen cells showed that approximately 20% of CD11c-negative cells (i.e. non-DC cell populations) expressed BAFF in naïve mice ( Fig. 3A and B), and this increased to 29.5% within 3 days of a P. yoelii YM infection (Fig. 3C ), but then dropped to 10.6% by day 7 (Fig.  3D ). This was not however, an absolute loss of BAFF + non-DCs, as total spleen cell numbers increase several-fold within 7 days of infection (data not shown), thus adjusting absolute numbers of non-DCs expressing BAFF to preinfection levels ( Fig. 3E ).
Transgenic BAFF mice can support MSP1 19 -specific ASC survival during malaria
To assess the overall contribution of BAFF to survival of ASCs during malaria, we compared the activation of MSP1 19 -specific MBCs in BAFF-Transgenic (BAFF-Tg) and WT mice, by P. yoelii YM malaria. BAFF-Tg mice have abundant oligomeric (60-mer) soluble BAFF (sBAFF) in their serum [28] . For testing, pooled spleen cells (containing MBCs and memory T cells) were taken from MSP1 19 -vaccinated mice (after resting the mice more than 12 weeks) and transferred into sublethally irradiated WT or BAFFTg mice. Thus, both cohorts of recipient mice had the same starting population of cells and any differences would be related to survival of ASCs that had differentiated from antigen-activated + DC subpopulations per spleen in naïve and P. yoelii 17XNL-infected mice at day 7 p.i. are shown. (A-I) Data are shown as mean ± SEM of 3-6 independently processed mice/group and are representative of 2-4 independent assays that gave similar results. (J) BAFF mRNA was compared with an average of three housekeeping genes by real-time PCR in total spleen DCs from day 7 p.i. with P. yoelii YM and P. yoelii 17XNL. Data are shown as the mean and range of mRNA levels obtained using RNA prepared in two independent experiments. Significance was analyzed using the nonparametric Mann-Whitney U test on pooled data from replicate experiments. *p = 0.0173; **p = 0.0238; ***p = 0.0286; ****p = 0.0136.
MBCs, a process normally dependent on BAFF expression on DCs [12, 19, 20 ]. These recipient mice were then either infected with P. yoelii YM, given MSP1 19 -boost, or given no stimulus, and MSP1 19 -specific ASCs were assessed after 4 days by ELISPOT (Fig. 4A) .
WT mice given MSP1 19 -boosts had on average 315 ASCs per spleen and this number decreased significantly (∼72%) following P. yoelii YM infections (Fig. 4B) . In contrast, BAFF-Tg mice had on average 860 ASCs per spleen following MSP1 19 -boosts and more than 200% more ASCs per spleen (∼1828 ASCs per spleen) following P. yoelii YM-infections (Fig. 4B ). MSP1 19 -specific ASCs were not detected in recipient mice without stimulus, indicating that all MSP1 19 -specific ASCs seen were induced by in vivo restimulation either by a MSP1 19 -boost or malaria infection. Overall, these studies found 21-fold more ASCs during P. yoelii YM malaria in the presence of excess transgenic sBAFF compared with WT mice (1828 versus 88 ASCs per spleen). By contrast, following MSP1 19 -boosts, excess sBAFF in transgenic mice only improved ASC-survival compared with that of WT mice by threefold (860 versus 315 ASCs per spleen). Studies on survival mediated by the vaccine were not undertaken, as BAFF-Tg mice survived lethal P. yoelii YM malaria independent of immunization (Fig. 4C) .
BAFF

+ DCs from infected mice can activate vaccine-specific MBCs
We then investigated whether the residual BAFF + DCs from mice infected with P. yoelii YM malaria were competent to activate MBCs. For this, total DC populations were isolated from spleens of naive or P. yoelii YM-infected mice, and BAFF + DCs were isolated from infected mice (Fig. 5A ). These DC populations were then pulsed with MSP1 19 and transferred into mice vaccinated with MSP1 19 , 14-17 weeks earlier. After 5 days, the numbers of IgGsecreting ASCs in the spleens of recipient mice were quantified using an MSP1 19 -specific-ELISPOT assay (Fig. 5B) . Similar to data in Figure 1 , MSP1 19 -vaccinated mice given DCs from infected mice had significantly (67%) fewer ASCs compared with those given DCs from naïve mice (Fig. 5B) . However, MSP1 19 -vaccinated mice given BAFF + DCs from infected mice had significantly (280%)
more ASCs compared with the total DC populations from naive mice (Fig. 5B) . Thus, the few DCs in infected mice that expressed BAFF were competent for the activation of MSP1 19 -specific MBCs. To determine whether the functional defect of malaria-induced DCs extended to other MBC responses, experiments were repeated in mice vaccinated with DT (Diptheria Toxoid). For this, mice were vaccinated with DT, rested for 20 weeks and then given DCs from naïve or P. yoelii YM-infected mice pulsed with DT. Mice vaccinated with DT and given DT-pulsed DCs from infected mice had significantly (78%) fewer DT-specific ASCs compared with those given DT-pulsed DCs from naïve mice (Fig. 5C ). However, BAFF + DCs generated similar numbers of DT-specific ASCs as DCs from naïve mice but 850% more than DT-pulsed total DCs from infected mice (Fig. 5C ). This suggests that the loss of BAFF expression on DCs during P. yoelii YM malaria significantly affected the survival of all vaccine-derived ASCs and was not specific to only the MSP1 19 -vaccine.
MBCs require direct BAFF signals
To determine if the loss of DCs capable of expressing BAFF directly affected B cells, we used B cell-restricted tumor necrosis factor receptor-associated factors 3-knockout mice (TRAF3KO) where B cells can function independent of BAFF but other cells still depend on this signal. The inactivation of TRAF3 expression was achieved specifically within B cells by crossing mice with the Traf3lox allele with the Cd19-CRE line [29] . Normally, BAFF signals to B cells leads to TRAF2-dependent depletion of TRAF3, which promotes survival [29] . Thus, B cells without TRAF2 and/or TRAF3 develop and survive independently of obligatory BAFF. However, other cells (e.g. T cells) in these mice are still dependent on BAFF. Groups of these TRAF3KO or their WT littermate controls were vaccinated with MSP1 19 and rested 12 or 17 weeks. One half of the mice in each group were then infected with P. yoelii YM and the other half given soluble MSP1 19 . After 5 days, the spleens were taken to quantify numbers of MSP1 19 -specific ASCs (Fig. 6) . 19 , rested for 14 weeks and either given 10 μg MSP1 19 or infected with P. yoelii YM. MSP1 19 -specific ASCs in the spleen were enumerated after 5 days by MSP1 19 -specific ELISPOT assay. The numbers of MSP1 19 -specific ASCs/spleen in TRAF3-knockout or WT mice, following either MSP1 19 -boost or P. yoelii YM infection are shown. Data are shown as mean ± SEM of five independently processed mice/group and are representative of two independent experiments that gave similar results. Significance was analyzed using the nonparametric Mann-Whitney U test on pooled data from replicate experiments. *p < 0.0161; **p < 0.0066. Figure 4 , WT mice had significantly reduced ASC survival during P. yoelii YM-malaria compared to WT mice boosted with MSP1 19 (Fig. 6) . However, the reverse was true in the TRAF3KO mice, where infection stimulated significantly better ASC survival in the infected mice than in those that received the MSP1 19 -boost. Thus, when MBC-derived ASCs are no longer dependent on BAFF signals for survival, as in the TRAF3KO mice, the infection stimulated better responses than the vaccine. This suggests that during malaria, BAFF is a key signal for survival of ASCs following their differentiation from activated MBCs.
Similar to the observations presented in
Discussion
This study found that despite the generation of MBC responses to MSP1 19 , a leading antimalarial vaccine candidate, their function was ablated due to loss of BAFF expression on cDCs during malaria. Conventional DCs are not the only cell type to express BAFF in the spleen, but they were the cells with the most profound loss of BAFF during the course of infection. This, together with the observations that BAFF-Tg mice or transfer of BAFF + DCs into vaccinated mice were able to elicit effective MBC responses, suggests that the overall loss of BAFF on cDCs-mediated poor support for activation of memory responses. Further, the significantly higher numbers of MSP1 19 -specific ASCs in TRAF3KO mice compared with those of WT mice during malarial infections is consistent with suboptimal BAFF signaling for survival of MBCs activated by the infection. Finally, the critical role of BAFF in protection during malaria was seen when BAFF-Tg mice survived lethal malaria. Together, these studies indicate that BAFF, a key signal required for maintenance of B-cell function, is compromised during malarial infections, limiting the effectiveness of MBC responses elicited by malaria vaccines. BAFF is a member of the TNF family of ligands, expressed on DCs, macrophages, neutrophils, and stromal cells [30] . BAFF supports B-cell proliferation [15] and plasma cell generation [19, 20, 31] . In contrast, the maintenance of MBCs in mice prior to activation is independent of BAFF [31] . This was noted when the administration of soluble BAFF receptors (BAFF-R or TACI) to vaccinated mice, to block BAFF activity, did not affect numbers of MBCs subsequently activated by antigen when BAFF activity was available [31] . However, BAFF was required for the survival of ASCs that differentiated from antigen-activated human MBCs [19, 20] via TACI signals [28] . Finally, TACI can only respond to oligomeric BAFF 60-mer but not the BAFF 3-mer, which is the main form of BAFF found in circulation [28] . We thus focused on the role of BAFF in survival of antigen-activated MBCs. In our studies, in addition to the significant role of BAFF in supporting MBC responses, we also noted that BAFF-Tg mice that have soluble BAFF 60-mers in their serum [28] , survived lethal malaria independent of vaccination. This finding indicates that BAFF also has a role in primary immunity against malaria. Furthermore, the significantly better survival of ASCs in malariainfected TRAF3KO mice compared with that of WT mice shows that the effect of BAFF is not on T-cell help, as only B cells were free from the requirement of obligatory BAFF in TRAF3KO mice.
A recent study suggested that BAFF was an indicator of disease severity during and after acute malaria in children, as it was found that serum BAFF levels increased during acute malarial infection that correlated with the severity of the disease [32] . Further, numbers of MBCs expressing TACI, the receptor for BAFF on MBCs increased following acute infection [32] . This observation appears to contradict our study. Another study reported that the soluble schizont fraction of P. falciparum antigens and hemozoin (HZ) could activate monocytes to express BAFF on their surface and release soluble BAFF into the supernatant within 72 h of stimulation [33] . However, studies have shown that TACI, the receptor for BAFF on MBCs, only mediates survival via oligomeric (60-mer) BAFF signals [28] . Given that the main form of soluble BAFF found in serum is only a 3-mer [28] , we propose that the soluble BAFF found in children with acute malaria may not activate MBCs. In contrast, we found oligomeric BAFF, which occurs in the serum of BAFF-Tg mice [28] did support ASCs. The 3-mer sBAFF may even prevent oligomeric BAFF from mediating survival of ASCs. These findings could explain why parasite-specific ASCs may not survive in children with acute malaria even though they appear to have soluble BAFF in their serum. Although we utilised the BAFFTg mice to show boosted ASC survival, we propose that the most relevant form of BAFF normally mediating ASC-survival is on the surface of the cDC.
Malaria is not the only infectious disease to be associated with a dysregulation of BAFF. In particular, high serum levels of BAFF at the onset of acute hepatitis C infections can predict its evolution into a chronic infection [34] . Similarly, high expression levels of BAFF by DCs correlate with higher HIV-related B-cell disease progression in humans [35] while the differential expression of BAFF receptors BMCA and BAFF-R increased the propensity of B-cell death during HIV infections [36] . Further, BAFF also contributes to the loss of various B-cell populations during Trypanosoma brucei infections in mice [37] . The role of dysregulated BAFF in mediating the severity of infectious diseases is emerging and needs consideration where vaccine development has been ineffective.
Only one malaria vaccine candidate out of a multitude has entered Phase IIIb clinical trials [38] , highlighting our incomplete understanding of malaria. However, new data strongly supports further consideration of MBCs in the field [3] . Our current studies, in rodent models, provide a mechanism that might explain why individuals in endemic areas fail to maintain parasite-specific MBCs [3] . We also suggest that MBC responses against malariavaccines cannot be boosted in endemic areas [4, 39] because the malaria parasite infects pDCs [40] that then are unable to support BAFF expression by cDCs (Fig. 2) , necessary to sustain ASC survival [12, 19, 20] . Finally, this study highlights a novel mechanism by which the malaria parasite prevents long-term immunity, and results suggest this may also compromise B-cell responses to coinfections with malaria.
Materials and methods
Animals
All animal studies were reviewed and approved by the QIMR Animal Ethics Committee (A02-626M) under National Health and Medical Research Council guidelines. Specific-pathogen-free 6-8 week old, female C57BL/6J mice were obtained from the Animal Resources Centre (Murdoch, Western Australia). The CD19 + conditional TRAF3KO mice were kindly provided by Dr. Robert Brink (Garvan Institute, Sydney, Australia) and BAFF-transgenic mice by Dr. Susan Kalled (Biogen Idec, Cambridge, MA, US), both on a C57BL/6 background.
Infection of mice
Groups of 3-15 C57BL/6J mice were infected intravenously with 10 4 lethal P. yoelii YM or 10 5 P. yoelii 17XNL infected RBCs (pRBCs), and spleens taken after 3, 7, or 10 days.
Immunization protocol for protection studies
Mice were vaccinated subcutaneously with 50 μg MSP1 19 in Freund's complete adjuvant per mouse, followed by three additional booster doses of 20 μg MSP1 19 in Freund's incomplete adjuvant given at 3-week intervals. The first booster dose was given subcutaneously followed by three doses given intraperitoneally. This protocol was shown previously to induce complete protection against a lethal infection given within 2-3 weeks of vaccination [8] . The mice were rested after the last immunization for 12-17 weeks to allow vaccine-specific primary T and B cells to subside and when only memory cells survive.
Isolation of spleen DCs for cell transfer studies
CD11c + DCs were obtained from spleens of naive mice or mice infected with either 10 4 P. yoelii YM (lethal) or 10 5 P. yoelii 17XNL (nonlethal) pRBCs. On day 4 of the lethal infection or day 7 of nonlethal infections, when parasitemia levels were approximately 5-10%, mice were treated with 250 μg Pyrimethamine (i.p.) daily for 3 days, to clear the infection. The P. yoelii YM infections were started 3 days after the P. yoelii 17XNL infections so that both groups of mice could be cured and tested at the same time. Infected mice were treated with Pyrimethamine, to clear the infection prior to isolation and transfer of DCs, to prevent transfer of parasites within DCs [40] . Previous studies showed that DCs taken from Pyrimethamine -treated P. yoelii 17XNL-infected mice remained functional [21] . Spleens from naive or infected mice were digested as previously described in [11] and in the supplementary section of [40] . RBCs were lysed with Gey's solution and the digested spleen cell suspension was then incubated with 100 μg/mL Rat IgG to block FcR binding of labeling antibodies. CD11c + DCs were isolated using Dynal and MACS microbeads as described in the main and supplementary section of [40] .
BAFF + DCs
To isolate BAFF + DCs, total DC populations were enriched as described using Dynal beads [40] , then labeled with anti-BAFF-FITC antibody and then with anti-FITC MACS microbeads for isolation on multiple MACS columns. BAFF + CD11c + DCs were then sorted on a MoFlo or ARIA cell sorter to obtain a purity of more than 98%.
DC transfer studies
Several groups of mice were vaccinated with MSP1 19 (Fig. 1) . The 20 mM EDTA was added to the wash buffer as it was previously shown to clear surface antigen, prior to transfer, so that the only source of the vaccine would be from within transferred DCs [11] . After a further 4 or 5 days, the number of MBCs that had differentiated into IgG-secreting ASCs in the spleen was quantified using an MSP1 19 or DT-specific-ELISPOT assay (Fig. 1A) .
Flow cytometry of DCs
To assess expression of BAFF on DCs and stroma, spleens from P. yoelii YM and P. yoelii 17XNL-infected mice on days 3 and 7 postinfection and from naïve mice were digested to release these cells. Cells were then labeled and examined by flow cytometry as described in the Supporting Information [40] .
ELISPOT assay
Multiscreen-HA plates were coated with 10 μg/mL MSP1 19 or DT in an alkaline carbonate buffer, overnight at 4 • C. Isolated spleen cells were directly tested for IgG-secreting ASCs using the published method [8] on these coated plates. The use of purified MSP1 19 or DT on the ELISPOT plates allowed measurement of vaccine-specific ASCs but not responses to the adjuvant. 19 -specific ELISPOT assay of recipients' total spleen cells. Of particular note, since BAFF-Tg and WT mice received similar numbers of total spleen cells from vaccinated mice, the numbers of memory B and T cells would also be the similar in both groups. Similarly, since TRAF3 deletion in TRAF3-KO mice was restricted to CD19 + B cells, T-cell function was similar in both WT and knockout mice. This also means that while B cells were free from the requirement for obligatory BAFF in knockout mice, T cells were still dependent on BAFF. TRAF3-KO mice were used to show that BAFF directly signaled B cells, and that the effect of BAFF was not on T cells.
BAFF-Transgenic (BAFF-Tg) mice and cell transfer studies
Real-time PCR
Groups of 3-5 C57BL/6 mice were infected with 10 4 P. yoelli YM and 10 5 P. yoelii 17XNL. Spleens were harvested after 7 days and CD11c + cells isolated as above. The cells were passed through the several MACS columns until purity was more than 99% as assessed by flow cytometry. Cells were lysed and RNA prepared by RNAeasy kit (Qiagen, Hilden, Germany). cDNA was synthesized using oligo (dT) priming, and levels of gene expression quantified by real-time PCR using Sybr Green and the CT method on an ABI 7900 machine (Applied Biosystems). Results for expression of BAFF were corrected for the amount of cDNA by using the average CT of three housekeeping genes, TATA-binding protein (TBP), CXXC1, and mRpl13a. The sequences of primers used were: BAFF -CACGCCGACTATACGAAAAGGA, BAFFr -TTGCCTCAC-CACTATTTTGTTCTCT, CXXC1f -CAGACGTCTTTTGGGTCCA, CXXC1r -AGACCTCATCAGCTGGCAC,TBPf -GACCTAAA-GACCATTGCACTTCGT, TBPr -GCAGTTGTCCGTGGCTCTCT, RPL13af -GAGGTCGGGTGGAAGTACCA, RPL13ar -TGCATCTTG-GCCTTTTCCTT.
Statistics
Except where noted, data shown are mean ± SEM. Statistical differences between groups were determined using the nonparametric Mann-Whitney U test on pooled data from replicate experiments, using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA) with p < 0.05 considered statistically significant.
